Immuneering (IMRX) Competitors $5.95 +1.06 (+21.68%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$5.90 -0.05 (-0.84%) As of 08/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX vs. SAGE, RAPP, SNDL, ZVRA, ARCT, SVRA, OPT, PVLA, SEPN, and ARVNShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Sage Therapeutics (SAGE), Rapport Therapeutics (RAPP), SNDL (SNDL), Zevra Therapeutics (ZVRA), Arcturus Therapeutics (ARCT), Savara (SVRA), Opthea (OPT), Palvella Therapeutics (PVLA), Septerna (SEPN), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Its Competitors Sage Therapeutics Rapport Therapeutics SNDL Zevra Therapeutics Arcturus Therapeutics Savara Opthea Palvella Therapeutics Septerna Arvinas Immuneering (NASDAQ:IMRX) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation. Which has more volatility and risk, IMRX or SAGE? Immuneering has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Do institutionals & insiders have more ownership in IMRX or SAGE? 67.7% of Immuneering shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 22.9% of Immuneering shares are held by company insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor IMRX or SAGE? In the previous week, Immuneering had 8 more articles in the media than Sage Therapeutics. MarketBeat recorded 8 mentions for Immuneering and 0 mentions for Sage Therapeutics. Immuneering's average media sentiment score of 0.13 beat Sage Therapeutics' score of 0.00 indicating that Immuneering is being referred to more favorably in the media. Company Overall Sentiment Immuneering Neutral Sage Therapeutics Neutral Do analysts recommend IMRX or SAGE? Immuneering currently has a consensus target price of $13.25, suggesting a potential upside of 122.69%. Sage Therapeutics has a consensus target price of $7.85, suggesting a potential downside of 9.56%. Given Immuneering's stronger consensus rating and higher probable upside, research analysts plainly believe Immuneering is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Sage Therapeutics 1 Sell rating(s) 13 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.93 Is IMRX or SAGE more profitable? Immuneering has a net margin of 0.00% compared to Sage Therapeutics' net margin of -427.78%. Sage Therapeutics' return on equity of -67.10% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets ImmuneeringN/A -146.28% -117.22% Sage Therapeutics -427.78%-67.10%-58.42% Which has better earnings and valuation, IMRX or SAGE? Immuneering has higher earnings, but lower revenue than Sage Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuneering$320K675.33-$61.04M-$1.89-3.15Sage Therapeutics$41.24M13.18-$400.67M-$4.89-1.78 SummaryImmuneering beats Sage Therapeutics on 11 of the 16 factors compared between the two stocks. Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.60M$3.12B$5.82B$9.74BDividend YieldN/A2.24%4.40%4.08%P/E Ratio-3.1520.6430.1425.84Price / Sales675.33351.71435.13105.64Price / CashN/A43.2325.7828.79Price / Book4.479.649.425.99Net Income-$61.04M-$54.08M$3.27B$265.29M7 Day Performance77.61%5.58%3.64%4.07%1 Month Performance46.55%4.11%3.52%0.93%1 Year Performance408.55%6.70%29.95%18.21% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering3.4854 of 5 stars$5.95+21.7%$13.25+122.7%+456.1%$177.60M$320K-3.1560News CoverageGap DownHigh Trading VolumeSAGESage Therapeutics3.3895 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690RAPPRapport Therapeutics1.883 of 5 stars$14.59-0.7%$29.50+102.2%-34.4%$536.70MN/A-5.84N/ASNDLSNDL1.6926 of 5 stars$2.16+6.9%$4.00+85.2%+13.7%$530.81M$671.81M-8.002,516ZVRAZevra Therapeutics3.3844 of 5 stars$9.20-2.4%$23.71+157.8%+30.4%$529.35M$23.61M-43.8120ARCTArcturus Therapeutics2.5694 of 5 stars$17.91-8.1%$50.00+179.2%-19.5%$528.97M$152.31M-8.03180Analyst ForecastSVRASavara3.2599 of 5 stars$3.05+0.3%$6.17+102.2%-28.1%$525.42MN/A-6.1020OPTOpthea0.2249 of 5 stars$3.41+7.2%$1.33-60.9%+18.8%$524.84M$120K0.008Positive NewsUpcoming EarningsGap UpHigh Trading VolumePVLAPalvella Therapeutics2.9075 of 5 stars$49.55+4.8%$57.10+15.2%N/A$523.12M$42.81M-4.10N/ASEPNSepterna1.6818 of 5 stars$11.59-1.1%$26.75+130.8%N/A$522.54M$1.08M-1.15N/AARVNArvinas3.9979 of 5 stars$7.17+1.1%$19.76+175.6%-71.4%$520.53M$263.40M-7.10420Positive News Related Companies and Tools Related Companies SAGE Alternatives RAPP Alternatives SNDL Alternatives ZVRA Alternatives ARCT Alternatives SVRA Alternatives OPT Alternatives PVLA Alternatives SEPN Alternatives ARVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access